#USA #New Orleans #Heart Disease #Thryv Therapeutics #SGK1 inhibitors

Thryv Therapeutics Set to Showcase Innovative Research at AHA 2025

Thryv Therapeutics Inc., a pioneering clinical-stage biotechnology firm, is making waves as it prepares to present its latest research at the American Heart Association's Scientific Sessions 2025 in New Orleans, Louisiana, taking place from November 8 to 10. The company is advancing a series of novel inhibitors targeting serum glucocorticoid inducible kinase 1 (SGK1), which show promise in treating life-threatening cardiac conditions such as inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies.

Highlights of the Presentation

During this prestigious event, Thryv will present new preclinical data that underscores the potential of SGK1 inhibition as a therapeutic strategy for addressing cardiovascular diseases, particularly heart failure. The discussions will feature prominent presentations by leading experts, which include:

• - Title: The serum and glucocorticoid regulated kinase 1 (SGK1) inhibitor THRV-1268 attenuates hallmarks of heart failure by reducing inflammation and fibrosis beyond sodium/glucose cotransporter 2 inhibition

Presenter: Dr. Saumya Das, MD, PhD, Co-Director of the Resynchronization and Advanced Cardiac Therapeutics Program at Massachusetts General Hospital.
Date/Time: Sunday, November 9, 2025, at 10:18–10:23 a.m. CT
Location: Clinical Science Zone 2, Poster 22

• - Title: THRV-1268, a potent and selective SGK1 inhibitor, improves adverse cardiac remodeling better than Jardiance® (empagliflozin) in heart failure.

Presenter: Dr. Saumya Das
Date/Time: Monday, November 10, 2025, at 10:45–10:50 a.m. CT
Location: Clinical Science Zone 1, Poster 5

• - Title: Small molecule inhibitors of serum glucocorticoid kinase 1 (SGK1) prevent cardiac structural and functional decline induced in a transverse aortic constriction (TAC) model.

Presenter: Dr. Amy Sehnert, MD, Chief Medical Officer of Thryv Therapeutics Inc.
Date/Time: Monday, November 10, 2025, at 11:06–11:11 a.m. CT
Location: Clinical Science Zone 1, Poster 5

Innovations in the SGK1 Inhibitor Program

At the center of Thryv Therapeutics’ research is THRV-1268, a groundbreaking SGK1 inhibitor with significant potential to transform the treatment of various critical cardiac conditions, such as Long QT Syndrome (LQTS), heart failure, and atrial fibrillation. Given the urgent need for effective therapies in these areas, Thryv is advancing its investigational new drug (IND) applications to initiate studies focusing on THRV-1268’s efficacy in both LQTS and heart failure.

Thryv's pipeline prominently features highly selective SGK1 inhibitors that target the underlying mechanisms responsible for electrical and structural remodeling in the heart. Understanding the pivotal role of SGK1 in regulating inflammatory and fibrotic processes gives Thryv an innovative edge in creating therapeutic solutions that seek to enhance patient outcomes in cardiovascular care.

Thryv Therapeutics: A Leading Force in Biotechnology

Based in Montreal, Quebec, Thryv Therapeutics Inc. is dedicated to employing precision medicine strategies to address genetic channelopathies, cardiometabolic diseases, and cardiomyopathies through highly selective SGK1 inhibitors. The company’s commitment to research and innovation positions it as a key player in the ongoing efforts to improve treatment modalities for serious medical conditions. For more details on Thryv Therapeutics and their groundbreaking work, please visit Thryv Therapeutics.

Thryv Therapeutics' participation at AHA 2025 is more than just a presentation; it's a step towards redefining how we approach cardiovascular health and addressing some of the most pressing unmet medical needs in this field.